DNA repair pathways and their implication in cancer treatment

Cancer and Metastasis Reviews

Volumn 29, Issue 4, 2010, Pages 677-685

  Pallis, Athanasios G ^a   Karamouzis, Michalis V ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b NONE

Author keywords

Cancer treatment; Cytotoxic drugs; DNA repair pathways

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 6 O BENZYLGUANINE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DIETHYLNITROSAMINE; DOUBLE STRANDED DNA; DOXORUBICIN; ETHYLNITROSOUREA; FLUOROURACIL; INO 1001; IRINOTECAN; LOMEGUATRIB; LOMUSTINE; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NITROSOUREA DERIVATIVE; OLAPARIB; OXALIPLATIN; PLATINUM DERIVATIVE; PROCARBAZINE; SINGLE STRANDED DNA; STREPTOZOCIN; TEMOZOLOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; COLORECTAL CANCER; DNA CROSS LINKING; DNA REPAIR; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; EARLY CANCER; ENDOMETRIUM CARCINOMA; EXCISION REPAIR; GLIOBLASTOMA; GLIOMA; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MELANOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIPLE MYELOMA; NEOPLASM; NUCLEOTIDE METABOLISM; OLIGODENDROGLIOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CROSS LINKING; REVIEW; SARCOMA; SINGLE STRANDED DNA BREAK; SOLID TUMOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS;

EID: 78449273620     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9258-8     Document Type: Review

References (87)

1. H Vermund FF Gollin 1968 Mechanisms of action of radiotherapy and chemotherapeutic adjuvants. A review Cancer 21 58 76 1:STN:280: DyaF1c%2Fpt1Wmuw%3D%3D 10.1002/1097-0142(196801)21:1<58::AID- CNCR2820210110>3.0.CO;2-5 4864247
2. DB Longley PG Johnston 2005 Molecular mechanisms of drug resistance The Journal of Pathology 205 275 292 1:CAS:528:DC%2BD2MXhsFOgsrk%3D 10.1002/path.1706 15641020
3. KK Khanna SP Jackson 2001 DNA double-strand breaks: Signaling, repair and the cancer connection Nature Genetics 27 247 254 1:CAS:528:DC%2BD3MXhslKqtLg%3D 10.1038/85798 11242102
4. KW Caldecott 2008 Single-strand break repair and genetic disease Nature Reviews Genetics 9 619 631 1:CAS:528:DC%2BD1cXpsVOku7Y%3D 18626472
5. LH Hurley 2002 DNA and its associated processes as targets for cancer therapy Nature Reviews Cancer 2 188 200 1:CAS:528:DC%2BD38Xis1KktL0%3D 10.1038/nrc749 11990855
6. R Hakem 2008 DNA-damage repair; the good, the bad, and the ugly The EMBO Journal 27 589 605 1:CAS:528:DC%2BD1cXitFKhsbk%3D 10.1038/emboj.2008.15 18285820
7. KA Olaussen A Dunant P Fouret E Brambilla F Andre V Haddad, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy The New England Journal of Medicine 355 983 991 1:CAS:528:DC%2BD28XpsFKmtLw%3D 10.1056/NEJMoa060570 16957145
8. AG Pallis L Serfass R Dziadziusko JP van Meerbeeck D Fennell D Lacombe, et al. 2009 Targeted therapies in the treatment of advanced/metastatic NSCLC European Journal of Cancer 45 2473 2487 1:CAS:528:DC%2BD1MXhtVKls7vN 10.1016/j.ejca.2009.06.005 19596191
9. B Sedgwick PA Bates J Paik SC Jacobs T Lindahl 2007 Repair of alkylated DNA: Recent advances DNA Repair (Amst) 6 429 442 1:CAS:528:DC%2BD2sXislWmt7k%3D 10.1016/j.dnarep.2006.10.005
10. MR Middleton GP Margison 2003 Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway The Lancet Oncology 4 37 44 1:CAS:528:DC%2BD3sXmsF2i 10.1016/S1470-2045(03)00959-8 12517538
11. S Sharma F Salehi BW Scheithauer F Rotondo LV Syro K Kovacs 2009 Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis Anticancer Research 29 3759 3768 1:CAS:528:DC%2BD1MXhsVOlt7vJ 19846906
12. D Leibeling P Laspe S Emmert 2006 Nucleotide excision repair and cancer Journal of Molecular Histology 37 225 238 1:CAS:528:DC%2BD28Xht1elsLjL 10.1007/s10735-006-9041-x 16855787
13. PC Hanawalt 2002 Subpathways of nucleotide excision repair and their regulation Oncogene 21 8949 8956 1:CAS:528:DC%2BD38XpsFSgsrw%3D 10.1038/sj.onc.1206096 12483511
14. WL de Laat NG Jaspers JH Hoeijmakers 1999 Molecular mechanism of nucleotide excision repair Genes & Development 13 768 785 10.1101/gad.13.7.768
15. A Aboussekhra M Biggerstaff MK Shivji JA Vilpo V Moncollin VN Podust, et al. 1995 Mammalian DNA nucleotide excision repair reconstituted with purified protein components Cell 80 859 868 1:CAS:528:DyaK2MXkslOmtbo%3D 10.1016/0092-8674(95)90289-9 7697716
16. H van Steeg KH Kraemer 1999 Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer Molecular Medicine Today 5 86 94 10.1016/S1357-4310(98)01394-X 10200950
17. LJ Niedernhofer H Odijk M Budzowska E van Drunen A Maas AF Theil, et al. 2004 The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks Molecular and Cellular Biology 24 5776 5787 1:CAS:528:DC%2BD2cXls1aqtro%3D 10.1128/MCB.24.13.5776-5787. 2004 15199134
18. RA Sharma GL Dianov 2007 Targeting base excision repair to improve cancer therapies Molecular Aspects of Medicine 28 345 374 1:CAS:528: DC%2BD2sXpvF2ktrg%3D 10.1016/j.mam.2007.06.002 17706275
19. KK Chan QM Zhang GL Dianov 2006 Base excision repair fidelity in normal and cancer cells Mutagenesis 21 173 178 1:CAS:528:DC%2BD28Xlt1OisLk%3D 10.1093/mutage/gel020 16613912
20. DM Wilson III VA Bohr 2007 The mechanics of base excision repair, and its relationship to aging and disease DNA Repair (Amst) 6 544 559 1:CAS:528:DC%2BD2sXislWmtbc%3D 10.1016/j.dnarep.2006.10.017
21. JC Ame C Spenlehauer G de Murcia 2004 The PARP superfamily Bioessays 26 882 893 1:CAS:528:DC%2BD2cXnt1CqtLk%3D 10.1002/bies.20085 15273990
22. W Min ZQ Wang 2009 Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential Frontiers in Bioscience 14 1619 1626 1:CAS:528: DC%2BD1MXltFeisr0%3D 10.2741/3329 19273151
23. JH Hoeijmakers 2001 Genome maintenance mechanisms for preventing cancer Nature 411 366 374 1:CAS:528:DC%2BD3MXktVSjs74%3D 10.1038/35077232 11357144
24. M Malanga FR Althaus 2005 The role of poly(ADP-ribose) in the DNA damage signaling network Biochemistry and Cell Biology 83 354 364 1:CAS:528: DC%2BD2MXntFClsbs%3D 10.1139/o05-038 15959561
25. AJ Chalmers 2009 The potential role and application of PARP inhibitors in cancer treatment British Medical Bulletin 89 23 40 1:CAS:528: DC%2BD1MXivFSiu7w%3D 10.1093/bmb/ldp005 19208614
26. J Jiricny 2006 The multifaceted mismatch-repair system Nature Reviews Molecular Cell Biology 7 335 346 1:CAS:528:DC%2BD28XjslSktrs%3D 10.1038/nrm1907 16612326
27. GM Li 2008 Mechanisms and functions of DNA mismatch repair Cell Research 18 85 98 1:CAS:528:DC%2BD1cXisVSjsA%3D%3D 10.1038/cr.2007.115 18157157
28. E Sonoda H Hochegger A Saberi Y Taniguchi S Takeda 2006 Differential usage of non-homologous end-joining and homologous recombination in double strand break repair DNA Repair (Amst) 5 1021 1029 1:CAS:528:DC%2BD28XptFSrsbo%3D 10.1016/j.dnarep.2006.05.022
29. MR Lieber 2008 The mechanism of human nonhomologous DNA end joining The Journal of Biological Chemistry 283 1 5 1:CAS:528:DC%2BD1cXhtVOnug%3D%3D 10.1074/jbc.R700039200 17999957
30. RD Johnson M Jasin 2001 Double-strand-break-induced homologous recombination in mammalian cells Biochemical Society Transactions 29 196 201 1:CAS:528:DC%2BD3MXkslentbk%3D 10.1042/BST0290196 11356153
31. Y Andegeko L Moyal L Mittelman I Tsarfaty Y Shiloh G Rotman 2001 Nuclear retention of ATM at sites of DNA double strand breaks The Journal of Biological Chemistry 276 38224 38230 1:CAS:528:DC%2BD3MXotFOqsr4%3D 11454856
32. CH Bassing FW Alt 2004 The cellular response to general and programmed DNA double strand breaks DNA Repair (Amst) 3 781 796 1:CAS:528: DC%2BD2cXmtVeqsLY%3D 10.1016/j.dnarep.2004.06.001
33. A Sabharwal MR Middleton 2006 Exploiting the role of O6-methylguanine- DNA-methyltransferase (MGMT) in cancer therapy Current Opinion in Pharmacology 6 355 363 1:CAS:528:DC%2BD28XmslGjsr4%3D 10.1016/j.coph.2006.03.011 16777483
34. SL Gerson 2004 MGMT: Its role in cancer aetiology and cancer therapeutics Nature Reviews Cancer 4 296 307 1:CAS:528:DC%2BD2cXis1Gmt70%3D 10.1038/nrc1319 15057289
35. M Esteller SR Hamilton PC Burger SB Baylin JG Herman 1999 Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Research 59 793 797 1:CAS:528:DyaK1MXht1Sjurk%3D 10029064
36. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha, et al. 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents The New England Journal of Medicine 343 1350 1354 1:CAS:528:DC%2BD3cXosFOltLg%3D 10.1056/ NEJM200011093431901 11070098
37. KA Jaeckle HJ Eyre JJ Townsend S Schulman HM Knudson M Belanich, et al. 1998 Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: A Southwest Oncology Group study Journal of Clinical Oncology 16 3310 3315 1:CAS:528:DyaK1cXmvFGrtbw%3D 9779706
38. ME Hegi AC Diserens S Godard PY Dietrich L Regli S Ostermann, et al. 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clinical Cancer Research 10 1871 1874 1:CAS:528: DC%2BD2cXisVGltbY%3D 10.1158/1078-0432.CCR-03-0384 15041700
39. MF Paz R Yaya-Tur I Rojas-Marcos G Reynes M Pollan L Guirre-Cruz, et al. 2004 CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas Clinical Cancer Research 10 4933 4938 1:CAS:528:DC%2BD2cXmtlSisbc%3D 10.1158/1078-0432.CCR-04-0392 15297393
40. MJ van den Bent HJ Dubbink M Sanson CR van der Lee-Haarloo M Hegi JW Jeuken, et al. 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951 Journal of Clinical Oncology 27 5881 5886 10.1200/JCO.2009.24.1034 19901104
41. GR Simon S Sharma A Cantor P Smith G Bepler 2005 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Chest 127 978 983 10.1378/chest.127.3.978 15764785
42. RV Lord J Brabender D Gandara V Alberola C Camps M Domine, et al. 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clinical Cancer Research 8 2286 2291 1:CAS:528:DC%2BD38XmtVWhsLw%3D 12114432
43. Y Shirota J Stoehlmacher J Brabender YP Xiong H Uetake KD Danenberg, et al. 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy Journal of Clinical Oncology 19 4298 4304 1:CAS:528: DC%2BD3MXptlGjtLk%3D 11731512
44. M Dabholkar J Vionnet F Bostick-Bruton JJ Yu E Reed 1994 Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy The Journal of Clinical Investigation 94 703 708 1:CAS:528:DyaK2cXlsVymsrg%3D 10.1172/JCI117388 8040325
45. R Metzger CG Leichman KD Danenberg PV Danenberg HJ Lenz K Hayashi, et al. 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy Journal of Clinical Oncology 16 309 316 1:CAS:528:DyaK1cXmsFeruw%3D%3D 9440758
46. C Welsh R Day C McGurk JR Masters RD Wood B Koberle 2004 Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines International Journal of Cancer 110 352 361 1:CAS:528:DC%2BD2cXktFeku78%3D 10.1002/ijc.20134
47. EV Stevens M Raffeld V Espina GB Kristensen CG Trope' EC Kohn, et al. 2005 Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma Cancer 103 2313 2319 1:CAS:528:DC%2BD2MXlsFSnt7k%3D 10.1002/cncr.21031 15844177
48. P Starostik T Manshouri S O'Brien E Freireich H Kantarjian M Haidar, et al. 1998 Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia Cancer Research 58 4552 4557 1:CAS:528:DyaK1cXmslWrs74%3D 9788599
49. M Korabiowska M Tscherny U Grohmann JF Honig SB Bartkowski C Cordon-Cardo, et al. 2002 Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity Anticancer Research 22 193 196 1:CAS:528:DC%2BD38XktF2mt7g%3D 12017286
50. Y Komuro T Watanabe Y Hosoi Y Matsumoto K Nakagawa N Tsuno, et al. 2002 The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma Cancer 95 1199 1205 10.1002/cncr.10807 12216085
51. Y Komuro T Watanabe Y Hosoi Y Matsumoto K Nakagawa S Saito, et al. 2003 Prediction of tumor radiosensitivity in rectal carcinoma based on p53 and Ku70 expression Journal of Experimental & Clinical Cancer Research 22 223 228 1:CAS:528:DC%2BD3sXls1Gjurg%3D
52. Y Komuro T Watanabe Y Hosoi Y Matsumoto K Nakagawa N Suzuki, et al. 2005 Prognostic significance of Ku70 protein expression in patients with advanced colorectal cancer Hepatogastroenterology 52 995 998 16001615
53. KR Brooks K To MB Joshi DH Conlon JE Herndon TA D'Amico, et al. 2003 Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: A novel approach for patient selection The Annals of Thoracic Surgery 76 187 193 10.1016/S0003-4975(03)00131-0 12842538
54. HW Taubert F Bartel M Kappler K Schuster A Meye C Lautenschlager, et al. 2003 Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients Cancer 97 2273 2278 1:CAS:528:DC%2BD3sXjvVSjsL4%3D 10.1002/cncr.11326 12712483
55. B Nakata YQ Wang M Yashiro M Ohira T Ishikawa H Nishino, et al. 2003 Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients Oncology Reports 10 997 1000 1:CAS:528: DC%2BD3sXltFGlt7c%3D 12792759
56. JW Catto G Xinarianos JL Burton M Meuth FC Hamdy 2003 Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability International Journal of Cancer 105 484 490 1:CAS:528:DC%2BD3sXktlOqsLo%3D 10.1002/ijc.11109
57. BH Son SH Ahn CD Ko IW Ka GY Gong JC Kim 2004 Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast The Breast Journal 10 20 26 1:CAS:528: DC%2BD2cXhvVGrsr0%3D 10.1111/j.1524-4741.2004.09609.x 14717755
58. H Arabi H Guan S Kumar M Cote S Bandyopadhyay C Bryant, et al. 2009 Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma Gynecological Oncology 113 153 158 1:CAS:528:DC%2BD1MXktlygtL4%3D 10.1016/j.ygyno.2009.02.004
59. C Bilbao PC Lara R Ramirez LA Henriquez-Hernandez G Rodriguez O Falcon, et al. 2010 Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer International Journal of Radiation Oncology, Biology, Physics 76 9 13 20005452
60. GG Des O Schischmanoff P Nicolas GY Perret JF Morere B Uzzan 2009 Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis European Journal of Cancer 45 1890 1896 10.1016/j.ejca.2009.04.018
61. P Benatti R Gafa D Barana M Marino A Scarselli M Pedroni, et al. 2005 Microsatellite instability and colorectal cancer prognosis Clinical Cancer Research 11 8332 8340 1:CAS:528:DC%2BD2MXht1KjsrnN 10.1158/1078-0432.CCR-05-1030 16322293
62. ST Kim J Lee SH Park JO Park HY Lim WK Kang, et al. 2010 Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy Cancer Chemotherapy and Pharmacology 66 659 667 1:CAS:528:DC%2BC3cXoslymtbc%3D 10.1007/s00280-009-1206-3 20033812
63. GG Des B Uzzan P Nicolas O Schischmanoff GY Perret JF Morere 2009 Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis Anticancer Research 29 1615 1620
64. AE Pegg 1990 Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents Cancer Research 50 6119 6129 1:CAS:528:DyaK3cXmtVOisLs%3D 2205376
65. M Gander S Leyvraz L Decosterd M Bonfanti C Marzolini F Shen, et al. 1999 Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours Annals of Oncology 10 831 838 1:STN:280:DyaK1MzpvFCmsA%3D%3D 10.1023/A:1008304032421 10470431
66. B Gerard S Aamdal SM Lee S Leyvraz C Lucas M D'Incalci, et al. 1993 Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma European Journal of Cancer 29A 711 719 1:STN:280:DyaK3s3ivFWgsg%3D%3D 10.1016/S0959-8049(05)80352-1 8471329
67. JA Quinn A Desjardins J Weingart H Brem ME Dolan SM Delaney, et al. 2005 Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma Journal of Clinical Oncology 23 7178 7187 1:CAS:528:DC%2BD2MXhtFCrsbfO 10.1200/JCO.2005.06.502 16192602
68. CW Ryan ME Dolan BB Brockstein R McLendon SM Delaney BL Samuels, et al. 2006 A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma Cancer Chemotherapy and Pharmacology 58 634 639 1:CAS:528:DC%2BD28Xns1SmsLo%3D 10.1007/s00280-006-0210-0 16520986
69. ED Batts C Maisel D Kane L Liu P Fu T O'Brien, et al. 2007 O6-benzylguanine and BCNU in multiple myeloma: A phase II trial Cancer Chemotherapy and Pharmacology 60 415 421 1:CAS:528:DC%2BD2sXmsVOjsr0%3D 10.1007/s00280-007-0442-7 17354015
70. A Sabharwal PG Corrie RS Midgley C Palmer J Brady P Mortimer, et al. 2010 A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer Cancer Chemotherapy and Pharmacology 66 829 835 1:CAS:528:DC%2BC3cXhtVSmt7bI 10.1007/s00280-009-1225-0 20039040
71. OA Khan M Ranson M Michael I Olver NC Levitt P Mortimer, et al. 2008 A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer British Journal of Cancer 98 1614 1618 1:CAS:528:DC%2BD1cXlvVWhtr0%3D 10.1038/sj.bjc.6604366 18475294
72. AJ Watson MR Middleton G McGown M Thorncroft M Ranson P Hersey, et al. 2009 O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib British Journal of Cancer 100 1250 1256 1:CAS:528:DC%2BD1MXksF2gs7g%3D 10.1038/sj.bjc.6605015 19367283
73. RF Kefford NP Thomas PG Corrie C Palmer E Abdi D Kotasek, et al. 2009 A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma British Journal of Cancer 100 1245 1249 1:CAS:528:DC%2BD1MXksF2gs78%3D 10.1038/sj.bjc.6605016 19367282
74. M Ranson P Hersey D Thompson J Beith GA McArthur A Haydon, et al. 2007 Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma Journal of Clinical Oncology 25 2540 2545 1:CAS:528: DC%2BD2sXotV2mt7k%3D 10.1200/JCO.2007.10.8217 17577032
75. L Liu Y Nakatsuru SL Gerson 2002 Base excision repair as a therapeutic target in colon cancer Clinical Cancer Research 8 2985 2991 1:CAS:528: DC%2BD38XnvVWit78%3D 12231545
76. Y Zhu J Hu Y Hu W Liu 2009 Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance Cancer Treatment Reviews 35 590 596 1:CAS:528:DC%2BD1MXhtlCgt73M 10.1016/j.ctrv.2009.06.005 19635647
77. JF Haince M Rouleau MJ Hendzel JY Masson GG Poirier 2005 Targeting poly(ADP-ribosyl)ation: A promising approach in cancer therapy Trends in Molecular Medicine 11 456 463 1:CAS:528:DC%2BD2MXhtVyms7vI 10.1016/j.molmed. 2005.08.003 16154385
78. Y Drew R Plummer 2009 PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications Drug Resistance Updates 12 153 156 1:CAS:528:DC%2BD1MXhsFagtLvN 10.1016/j.drup.2009.10.001 19939726
79. H Farmer N McCabe CJ Lord AN Tutt DA Johnson TB Richardson, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917 921 1:CAS:528:DC%2BD2MXjtFOmsrc%3D 10.1038/nature03445 15829967
80. Fong, P. C., Boss, D. S., Carden, C. P., Roelvink, M., DeGreve, J., Gourley, C. M., et al. (2008). AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology, 26, abstr 5510.
81. Audeh, M. W., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., et al. (2009). Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. Journal of Clinical Oncology, 27, abstr 5500.
82. Tutt, A., Robson, M., Garber, E., Domchek, S., Audeh, M. W., Weitzel, J. N., et al. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Journal of Clinical Oncology, 27, abstr CRA501.
83. Plummer, R., Lorigan, P., Evans, J., Steven, N., Middleton, M., Wilson, R., et al. (2006). First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Journal of Clinical Oncology, 24, abstr 8013.
84. AY Bedikian NE Papadopoulos KB Kim WJ Hwu J Homsi MR Glass, et al. 2009 A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma Cancer Investigation 27 756 763 1:CAS:528:DC%2BD1MXpt1Kitbc%3D 10.1080/07357900802709159 19440934
85. S Kummar R Kinders ME Gutierrez L Rubinstein RE Parchment LR Phillips, et al. 2009 Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies Journal of Clinical Oncology 27 2705 2711 1:CAS:528:DC%2BD1MXnslWitLs%3D 10.1200/JCO.2008.19.7681 19364967
86. R Plummer C Jones M Middleton R Wilson J Evans A Olsen, et al. 2008 Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors Clinical Cancer Research 14 7917 7923 1:CAS:528:DC%2BD1cXhsVegt7%2FM 10.1158/1078-0432.CCR-08- 1223 19047122
87. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers The New England Journal of Medicine 361 123 134 1:CAS:528:DC%2BD1MXosVKrtrw%3D 10.1056/NEJMoa0900212 19553641